<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069352</url>
  </required_header>
  <id_info>
    <org_study_id>M16-043</org_study_id>
    <secondary_id>2016-003900-30</secondary_id>
    <nct_id>NCT03069352</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white
      blood cell responsible for fighting infections). Successful treatment of AML is dependent on
      what subtype of AML the patient has, and the age of the patient when diagnosed.

      Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a
      cell) that allows cancer cells to stay alive. This study is designed to see if adding
      venetoclax to cytarabine works better than cytarabine on its own.

      This is a Phase 3, randomized, double-blind (treatment unknown to patients and doctors),
      placebo-controlled, multicenter study in patients with AML who are 18 or more years old and
      have not been treated before. Patients who take part in this study should not be sutiable for
      intensive induction chemotherapy (usual starting treatment). Abbvie is funding this study
      which will take place at approximately 125 hospitals globally and enrol approximately 175
      patients. In this study, 2/3 of patients will receive venetoclax every day with cytarabine
      and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine.

      Patients will continue to have study visits and receive treatment for as long as they are
      having a clinical benefit. The effect of the treatment on AML will be checked by taking
      blood, bone marrow, scans, measuring side effects and by completing health questionnaires.
      Blood and bone marrow tests will be completed to see why some people respond better than
      others. Additional blood tests will be completed for genetic factors and to see how long the
      drug remains in the body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">November 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Measured up to 2 years after the last participant is enrolled</time_frame>
    <description>OS is defined as the number of days from the date of randomization to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Up to 2 years after the last participant is enrolled</time_frame>
    <description>EFS will be defined as the number of days from randomization to the date of progressive disease, relapse from CR to CRi, treatment failure, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Complete Remission Rate by Initiation of Cycle 2</measure>
    <time_frame>Up to 6 months after the last participant is randomized</time_frame>
    <description>This will be calculated based on the modified International Working Group (IWG) criteria. CR is defined as absolute neutrophil count greater than 10^3/ microliter (mcL), platelets greater than or equal to 10^5/mcL, red cell transfusion independence, and bone marrow with less than 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of less than 10^3/mcL or thrombocytopenia less than or equal to 10^5/mcL (100,000/mcL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Up to 2 years after the last participant is enrolled</time_frame>
    <description>Additional subscales and items from EORTC QLQ-C30 will be evaluated using a linear mixed effects regression model to test for differences between the two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>Up to 2 years after the last participant is enrolled</time_frame>
    <description>The proportion of subjects with complete remission (CR) will be calculated based on the modified IWG criteria for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Complete Remission Rate</measure>
    <time_frame>Up to 2 years after the last participant is randomized</time_frame>
    <description>This will be calculated based on the modified International Working Group (IWG) criteria. CR is defined as absolute neutrophil count greater than 10^3/ microliter (mcL), platelets greater than or equal to 10^5/mcL, red cell transfusion independence, and bone marrow with less than 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of less than 10^3/mcL or thrombocytopenia less than or equal to 10^5/mcL (100,000/mcL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Up to 2 years after the last participant is enrolled</time_frame>
    <description>Exploratory research will be conducted on the subscales and items from the PROMIS Fatigue SF 7a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Up to 2 years after the last participant is enrolled</time_frame>
    <description>Exploratory research will be conducted on the subscales and items from EORTC QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Up to 2 years after the last participant is enrolled</time_frame>
    <description>Exploratory research will be conducted on the subscales and items from EQ--5D-5L.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Venetoclax + Low Dose Cytarabine (LDAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 600 mg orally every day (QD) QD on Days 1 - 28 plus LDAC 20 mg/m^2 subcutaneously QD on Days 1 - 10 (28 day cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + LDAC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo for Venetoclax 600 mg orally QD on Days 1 - 28 plus LDAC 20 mg/m^2 subcutaneous QD on Days 1 - 10 (28 day cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo + LDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet</description>
    <arm_group_label>Venetoclax + Low Dose Cytarabine (LDAC)</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>Venclaxta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Subcutaneous</description>
    <arm_group_label>Venetoclax + Low Dose Cytarabine (LDAC)</arm_group_label>
    <arm_group_label>Placebo + LDAC</arm_group_label>
    <other_name>Cytosar-U</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Arabinosylcytosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have histological confirmation of Acute Myeloid Leukemia (AML) by
             World Health Organization criteria, be ineligible for intensive induction chemotherapy
             and either be:

               1. ≥ 75 years of age OR

               2. ≥ 18 to 74 years of age and fulfill at least one criteria associated with lack of
                  fitness for intensive induction chemotherapy:

             i. Eastern Cooperative Oncology Group (ECOG) Performance status of 2 - 3; ii. Cardiac
             history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction ≤
             50% or chronic stable angina; iii. Diffusing Capacity of the Lung for Carbon Monoxide
             (DLCO) ≤ 65% or Forced Expiratory Volume in 1 second(FEV1) ≤ 65%; iv. Creatinine
             clearance ≥ 30 mL/min to &lt; 45 ml/min; v. Moderate hepatic impairment with total
             bilirubin &gt; 1.5 to ≤ 3.0 × Upper Limit of Normal (ULN); vi. Other comorbidity that the
             physician judges to be incompatible with conventional intensive chemotherapy which
             must be reviewed and approved by the study medical monitor before study enrollment.

          -  Participant must have an ECOG Performance status:

               1. of 0 to 2 for participants ≥ 75 years of age or

               2. of 0 to 3 for participants between 18 to 74 years of age.

          -  Participant must have a projected life expectancy of at least 12 weeks.

          -  Participant must have adequate renal function as demonstrated by a creatinine
             clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by
             24-hours urine collection.

          -  Participant must have adequate liver function as demonstrated by:

             a. aspartate aminotransferase (AST) ≤ 3.0 × ULN* b. alanine aminotransferase (ALT) ≤
             3.0 × ULN* c. bilirubin ≤ 1.5 × ULN* i. Subjects who are &lt; 75 years of age may have
             bilirubin of ≤ 3.0 × ULN

             * Unless considered to be due to leukemic organ involvement.

          -  Female participants must be either postmenopausal defined as:

               1. Age &gt; 55 years with no menses for 12 or more months without an alternative
                  medical cause.

               2. Age ≤ 55 years with no menses for 12 or more months without an alternative
                  medical cause AND an FSH level &gt; 40 IU/L; or

               3. Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or
                  hysterectomy); or

               4. A Woman of Childbearing Potential (WOCBP) practicing at least one protocol
                  specified method of birth control starting at Study Day 1 through at least 180
                  days after the last dose of study drug.

          -  Male participants who are sexually active, must agree, from Study Day 1 through at
             least 180 days after the last dose of study drug, to practice protocol specified
             methods of contraception. Male subjects must agree to refrain from sperm donation from
             initial study drug administration through at least 180 days after the last dose of
             study drug.

          -  Females of childbearing potential must have negative results for pregnancy test
             performed:

               1. At Screening with a serum sample obtained within 14 days prior to the first study
                  drug administration, and

               2. Prior to dosing with urine sample obtained on Week 1 Day 1, if it has been &gt; 7
                  days since obtaining the serum pregnancy test results.

               3. Participants with borderline pregnancy tests at Screening must have a serum
                  pregnancy test ≥ 3 days later to document continued lack of a positive result.

          -  Participant must voluntarily sign and date an informed consent form, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any screening or study-specific procedures.

        Exclusion Criteria:

          -  Participant has received any prior treatment for AML with the exception of
             hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment
             for Myelodysplastic Syndrome is allowed except for use of cytarabine.

          -  Participant had an antecedent myeloproliferative neoplasm (MPN) including
             myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous
             leukemia (CML) with or without BCR-ABL 1 translocation and AML with BRC-ABL 1
             translocation.

          -  Participants that have acute promyelocytic leukemia (APL).

          -  Participant has known Central Nervous System (CNS) involvement with AML.

          -  Participant has known Human Immunodeficiency Virus (HIV) infection (due to potential
             drug-drug interactions between antiretroviral medications and venetoclax). HIV testing
             will be performed at Screening, if required per local guidelines or institutional
             standards.

          -  Participant is known to be positive for hepatitis B virus (HBV), or hepatitis C virus
             (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on
             antivirals (non-exclusionary medications) are not excluded.

          -  Participant has received strong or moderate CYP3A inducers 7 days prior to the
             initiation of study treatment.

          -  Participant has consumed grapefruit, grapefruit products, Seville oranges (including
             marmalade containing Seville oranges) or Star fruit within 3 days prior to the
             initiation of study treatment.

          -  Participant has cardiovascular disability status of New York Heart Association Class &gt;
             2.

        Class 2 is defined as cardiac disease which subjects are comfortable at rest but ordinary
        physical activity results in fatigue, palpitations, dyspnea, or angina pain.

        Class 3 is defined as cardiac disease which subjects are comfortable at rest but less than
        ordinary activity causes fatigue, palpitation, or dyspnea.

        Class 4 is defined as cardiac disease which subjects have an inability to carry on any
        physical activity without discomfort, symptoms of heart failure at rest, and if any
        physical activity is undertaken then discomfort increases.

          -  Participant has chronic respiratory disease that requires continuous oxygen, or
             significant history of renal, neurologic, psychiatric, endocrinologic, metabolic,
             immunologic, hepatic, cardiovascular disease, any other medical condition or known
             hypersensitivity to any of the study medications including excipients of LDAC that in
             the opinion of the investigator would adversely affect his/her participating in this
             study.

          -  Participant has a malabsorption syndrome or other condition that precludes enteral
             route of administration.

          -  Participant exhibits evidence of other clinically significant uncontrolled systemic
             infection requiring therapy (viral, bacterial or fungal).

          -  Participant has a history of other malignancies prior to study entry, with the
             exception of:

               1. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of
                  breast;

               2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
                  skin;

               3. Previous malignancy confined and surgically resected (or treated with other
                  modalities) with curative intent.

          -  Participant has a white blood cell count &gt; 25 × 109/L. (Note: Hydroxyurea
             administration or leukapheresis is permitted to meet this cr
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-3700</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Med Ctr</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ TX, MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raya Mawad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEMIC</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1431</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Oncologicas</name>
      <address>
        <city>Florianopolis</city>
        <state>Santa Catarina</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital do Cancer Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90470-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casa de Saúde Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos</name>
      <address>
        <city>Sao Paulo</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CISSS de la Monteregie</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre Coeur Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hosp of Jilin Univ</name>
      <address>
        <city>Changchun</city>
        <state>Anhui</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hosp Southern Med Univ</name>
      <address>
        <city>Guangzhou</city>
        <state>Anhui</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Tongji Medical</name>
      <address>
        <city>Wuhan, Hubei</city>
        <state>Henan</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital,College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujian Medical Univ Union Hosp</name>
      <address>
        <city>Fuzhou</city>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <zip>250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong Univ</name>
      <address>
        <city>Jinan</city>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blood Disease Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou, Henan</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Ostrava-Poruba</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakult Nem Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite CEDEX</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans CEDEX 9</city>
        <state>Sarthe</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Cote</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar-Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wurttemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Laiko</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gen Univ Hosp Alexandroupolis</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gen Hosp Athens Evangelismos</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Gen Hosp of Patra</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;George Papanikolaou&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet</name>
      <address>
        <city>Budapest IX</city>
        <state>Budapest</state>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pécs</city>
        <state>Pecs</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem I. Belklini</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Koz</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korh</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor Oktato Korhaz</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin 8</city>
        <state>Dublin</state>
        <zip>D08 E9P6</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D09 XR63</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <zip>V94F858</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Mito Medical Center</name>
      <address>
        <city>Higashi Ibaraki-gun</city>
        <state>Ibaraki</state>
        <zip>3113193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefect Univ Med</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>〒852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>〒545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Jikei Daisan Hospital</name>
      <address>
        <city>Komae-shi</city>
        <state>Tokyo</state>
        <zip>201-8601</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital</name>
      <address>
        <city>Akita</city>
        <zip>100041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Med Univ Int Med Ctr</name>
      <address>
        <city>Hidaka</city>
        <zip>350-1241</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunmaken Saiseikai Maebashi Ho</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization</name>
      <address>
        <city>Nagoya</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hosp</name>
      <address>
        <city>Shimotsuga</city>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hosp</name>
      <address>
        <city>Busan</city>
        <state>Busan Gwang Yeogsi</state>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon Gwang Yeogsi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cath Univ Seoul St Mary's Hosp</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerol</name>
      <address>
        <city>Ciudad de México</city>
        <state>Ciudad De Mexico</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Invest Clin Chapulte</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58260</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Dr. Jose E. Gonz</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64320</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middlemore Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Ostfold Kalnes</name>
      <address>
        <city>Gralum</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System</name>
      <address>
        <city>San Juan</city>
        <zip>00921-3201</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod regional clinical hospital named N. A. Semashko</name>
      <address>
        <city>Nizhnij Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Health of the &quot;Ryazan Regional Clinical Hospital&quot;</name>
      <address>
        <city>Ryazan</city>
        <state>Ryazanskaya Oblast</state>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital Botkina</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samara State Medical Universit</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almazov North-West Federal Med</name>
      <address>
        <city>Sankt-peterburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical</name>
      <address>
        <city>Saratov</city>
        <zip>41002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Institu</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinic Hosp</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Netcare Pretoria East Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tshwane District Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univ Hosp</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

